RESUMEN
Non-competitive 2-site radioimmunoassays (RIA) for the determination of the complement proteins C1q, C4 and C3 in cerebrospinal fluid (CSF) are described. The quantitative results of the RIAs were the same as those obtained by other assay methods: radial immunodiffusion and turbidimetry and, in the case of C4, the haemolytic assay. The concentrations of the complement proteins in paired CSF and serum samples from a group of 60 patients were measured, as well as those of albumin and IgG. The ratios (concentration in CSF)/(concentration in serum) of the complement proteins correlated poorly with that of albumin. In contrast, the ratio of IgG was significantly correlated with that of albumin. The ratios of the complement proteins were higher than might be expected on the basis of their molecular masses. This suggests that these proteins may be synthesized within the normal central nervous system.
Asunto(s)
Enzimas Activadoras de Complemento/líquido cefalorraquídeo , Complemento C3/líquido cefalorraquídeo , Complemento C4/líquido cefalorraquídeo , Adolescente , Adulto , Anciano , Enzimas Activadoras de Complemento/sangre , Enzimas Activadoras de Complemento/normas , Complemento C1q , Complemento C3/normas , Complemento C4/normas , Estabilidad de Medicamentos , Femenino , Humanos , Inmunodifusión , Masculino , Persona de Mediana Edad , Radioinmunoensayo/normas , Estándares de Referencia , Valores de ReferenciaRESUMEN
Determination of the C1q content of cerebrospinal fluid (CSF) may be of value in understanding the immunological reactions occurring within the central nervous system (CNS). A double sandwich ELISA method has been developed for the detection of C1q in human serum and CSF. It uses polyclonal antibodies and is sensitive in the nanogram range. The mean concentrations of C1q were determined to be 127 micrograms/ml in serum and 0.4 microgram/ml in CSF. These results suggest that increased levels of C1q in the CSF play a role in some neurodegenerative disorders.
Asunto(s)
Enzimas Activadoras de Complemento/líquido cefalorraquídeo , Complemento C1/líquido cefalorraquídeo , Ensayo de Inmunoadsorción Enzimática , Adolescente , Adulto , Anciano , Enfermedad de Alzheimer/sangre , Enfermedad de Alzheimer/líquido cefalorraquídeo , Esclerosis Amiotrófica Lateral/sangre , Esclerosis Amiotrófica Lateral/líquido cefalorraquídeo , Enzimas Activadoras de Complemento/análisis , Enzimas Activadoras de Complemento/normas , Complemento C1/análisis , Complemento C1/normas , Complemento C1q , Ensayo de Inmunoadsorción Enzimática/normas , Humanos , Inmunodifusión , Persona de Mediana Edad , Estándares de ReferenciaRESUMEN
An assay for circulating immune complexes (CIC) that is adaptable to a routine clinical laboratory is described. This solid phase C1q (SP C1q) enzyme immunoassay (EIA) uses commercially available reagents and is reproducible with CV% of less than 20% in the abnormal range. We also demonstrate the specificity of the assay for detecting clinically relevant dsDNA-anti-DNA immune complexes.